Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Milestone ScientificMLSS -10.47%37 Cash-to-Debt is 3.36 as of Jun. 2026, which is 82% below its 10-year median of 18.62. GuruFocus rates MLSS with a GF Score™ of 37/100 and a GF Value™ of $0.60 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 847 Medical Devices & Instruments companies, Milestone Scientific ranks better than 60.09% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Milestone Scientific's cash to debt ratio for the quarter that ended in Jun. 2026 was 3.36.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Milestone Scientificcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Milestone Scientific's Cash-to-Debt or its related term are showing as below:
MLSS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.07 Med: 18.62 Max: No Debt
Current: 3.36
During the past 13 years, Milestone Scientific's highest Cash to Debt Ratio was No Debt. The lowest was 1.07. And the median was 18.62.
MLSS's Cash-to-Debt is ranked better than 60.09% of 847
companies
in the Medical Devices & Instruments industry
Industry Median: 1.68
vs MLSS: 3.36
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Milestone Scientific Cash-to-Debt Related Terms
Milestone Scientific Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Milestone Scientific's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Instruments & Supplies subindustry, Milestone Scientific's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Milestone Scientific Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Milestone Scientific's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Milestone Scientific's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Milestone Scientific (MLSS) has a Cash-to-Debt of 3.36 as of Jun. 2026. This is 82% below median its historical median of 18.62. Over the past decade, Milestone Scientific's Cash-to-Debt has ranged from 1.07 to 10,000.00. According to the industry distribution chart, Milestone Scientific ranks #338 out of 847 companies in the Medical Devices & Instruments industry, placing it in the top 39.9%.
Is Milestone Scientific's Cash-to-Debt too high?
Milestone Scientific's current Cash-to-Debt of 3.36 is 82% below median its 10-year median of 18.62. Over the past 10 years, this metric has ranged from a low of 1.07 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.68. Milestone Scientific's value of 3.36 is 100% above this industry median. Based on the distribution chart, Milestone Scientific ranks #338 out of 847 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Milestone Scientific has a GF Score™ of 37/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Milestone Scientific's Cash-to-Debt compare to NEPH and HBIO?
According to the Medical Devices & Instruments industry distribution chart, Milestone Scientific ranks #338 out of 847 companies for Cash-to-Debt. This puts Milestone Scientific in the upper half of its industry. The industry median Cash-to-Debt is 1.68. Milestone Scientific's value of 3.36 is 100% above this benchmark. Historically, Milestone Scientific's own Cash-to-Debt has ranged from 1.07 to 10,000.00 over the past decade. While the company's 10-year median is 18.62 vs. the industry median of 1.68, Milestone Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.68, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Milestone Scientific's current Cash-to-Debt of 3.36 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Milestone Scientific's current Cash-to-Debt is 3.36, which is 82% below median its own 10-year median of 18.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Milestone Scientific stock overvalued right now?
Based on GuruFocus' analysis, Milestone Scientific (MLSS) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.60, compared to a current price of $0.50 — trading 17.5% below its estimated fair value. The current Cash-to-Debt is 3.36, which is 82% below median its 10-year median of 18.62 and 100% above the Medical Devices & Instruments industry median of 1.68. Milestone Scientific's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Milestone Scientific (MLSS), the current Cash-to-Debt is 3.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Milestone Scientific (MLSS) Overvalued in 2026?
Based on GuruFocus' analysis, Milestone Scientific stock appears to be undervalued.
The current stock price of $0.50 is trading 17.5% below its estimated GF Value™ of $0.60.
GuruFocus considers Milestone Scientific to be Modestly Undervalued.
Key valuation signals for MLSS:
Cash-to-Debt: 3.36 (82% below median its 10-year median of 18.62)
GF Value™: $0.60 vs. price of $0.50 (17.5% below fair value)
Industry Position: 100% above the Medical Devices & Instruments median (#338 of 847)
No single metric tells the full story. See the MLSS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.
37GF Score
Get the complete analysis for MLSS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLSS has been successfully added to your 
